Suppr超能文献

慢性稳定型心绞痛患者管理指南:治疗

Guidelines for the management of patients with chronic stable angina: treatment.

作者信息

Fihn S D, Williams S V, Daley J, Gibbons R J

机构信息

NW Health Services Research and Development Center of Excellence, VA Puget Sound Health Care System 152, 1660 South Columbian Way, Seattle, WA 98108, USA.

出版信息

Ann Intern Med. 2001 Oct 16;135(8 Pt 1):616-32. doi: 10.7326/0003-4819-135-8_part_1-200110160-00014.

Abstract

The dual aims of treating patients with chronic stable angina are 1) to reduce morbidity and mortality and 2) to eliminate angina with minimal adverse effects and allow the patient to return to normal activities. In the absence of contraindications, beta-blockers are recommended as initial therapy. All beta-blockers seem to be equally effective. If the patient has serious contraindications to beta-blockers, unacceptable side effects, or persistent angina, calcium antagonists should be administered. Long-acting dihydropyridine and nondihydropyridine agents are generally as effective as beta-blockers in relieving angina. Long-acting nitrates are considered third-line therapy because a nitrate-free interval is required to avoid developing tolerance. All long-acting nitrates seem to be equally effective. Patients with angina should take 75 to 325 mg of aspirin daily unless they have contraindications. Such risk factors as smoking, elevated low-density lipoprotein cholesterol level, diabetes, and hypertension should be treated appropriately. Coronary revascularization has not been shown to improve survival for most patients with chronic angina but may be required to control symptoms. However, coronary artery bypass grafting (CABG) is often indicated for symptomatic patients with left-main disease, three-vessel disease, or two-vessel disease including proximal stenosis of the left anterior descending coronary artery; it improves their survival. Percutaneous transluminal coronary angioplasty is an alternative to CABG for patients with normal left ventricular function and favorable angiographic features. Coronary artery bypass grafting is initially more effective in relieving angina than medical therapy, but the two procedures yield similar results after 5 to 10 years. Eighty percent of patients who undergo CABG remain angina-free 5 years after surgery. In low-risk patients, percutaneous transluminal coronary angioplasty seems to control angina better than medical therapy, but recurrent angina and repeated procedures are more likely than with CABG. Patient education is an important component of management. Long-term follow-up should be individualized to ascertain clinical stability at regular intervals and to reassess prognosis when warranted.

摘要

治疗慢性稳定型心绞痛患者的双重目标是

1)降低发病率和死亡率;2)消除心绞痛,同时使不良反应最小化,并让患者恢复正常活动。在没有禁忌证的情况下,推荐使用β受体阻滞剂作为初始治疗。所有β受体阻滞剂似乎都同样有效。如果患者有β受体阻滞剂的严重禁忌证、不可接受的副作用或持续性心绞痛,则应给予钙拮抗剂。长效二氢吡啶类和非二氢吡啶类药物在缓解心绞痛方面通常与β受体阻滞剂同样有效。长效硝酸盐类被视为三线治疗药物,因为需要有一个无硝酸盐间期以避免产生耐受性。所有长效硝酸盐类似乎都同样有效。心绞痛患者除非有禁忌证,应每日服用75至325毫克阿司匹林。吸烟、低密度脂蛋白胆固醇水平升高、糖尿病和高血压等危险因素应得到适当治疗。对于大多数慢性心绞痛患者,冠状动脉血运重建尚未显示能改善生存率,但可能需要进行以控制症状。然而,冠状动脉旁路移植术(CABG)通常适用于有症状的左主干病变、三支血管病变或包括左前降支冠状动脉近端狭窄的两支血管病变患者;这可提高他们的生存率。对于左心室功能正常且血管造影特征良好的患者,经皮腔内冠状动脉成形术是CABG的替代方法。冠状动脉旁路移植术最初在缓解心绞痛方面比药物治疗更有效,但5至10年后这两种方法产生相似的结果。接受CABG的患者中有80%在术后5年仍无心绞痛。在低风险患者中,经皮腔内冠状动脉成形术似乎比药物治疗能更好地控制心绞痛,但与CABG相比,复发性心绞痛和重复手术的可能性更大。患者教育是管理的重要组成部分。长期随访应个体化,以便定期确定临床稳定性,并在必要时重新评估预后。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验